Entecavir Description

Entecavir is an articulate antiviral biologic acclimated in the analysis of hepatitis B infection. It is marketed beneath the barter name Baraclude (BMS).

Entecavir is a guanine alternation that inhibits all three accomplish in the viral archetype process, and the architect claims that it is added active than antecedent agents acclimated to amusement hepatitis B (lamivudine and adefovir). It was accustomed by the U.S. Food and Biologic Administration (FDA) in March 2005.

Entecavir is a guanosine nucleoside alternation with careful action adjoin hepatitis B virus (HBV). It is advised to selectively arrest the Hepatitis B virus, blocking all three accomplish in the archetype process. Entecavir is added able than an earlier Hepatitis B drug, lamivudine.

By aggressive with the accustomed substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): abject priming, about-face archetype of the abrogating fiber from the pregenomic agent RNA, and amalgam of the absolute fiber of HBV DNA. Upon activation by kinases, the biologic can be congenital into the DNA which has the ultimate aftereffect of inhibiting the HBV polymerase activity.